VP External Affairs & Business Development
SynOx Therapeutics, Netherlands
Sander is working as Vice President External Affairs & Business Development at SynOx Therapeutics and working on the development of the CSF-1R monocolonal antibody emactuzumab for TGCT and other macrophage mediated diseases.
He has large experience in translational research and early and late phase clinical development with medical and regulatory as well as business development responsibilities. Sander is known for his passion and energy for collaboration and establishing strong relationships. Sander has been key in successful global product launches of innovative targeted medicine in oncology, haematology and other therapeutic areas for patients with severe and rare diseases at different (bio)pharmaceutical companies where he fulfilled global strategic, operational and executive leadership positions.
Sander graduated as a Pharmacist and holds a registration as Clinical Pharmacologist from the University of Utrecht and completed his PhD in Medical Oncology and Clinical Pharmacology at the Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
